Aberrant lymphatic development in euploid fetuses with increased nuchal translucency including Noonan syndrome

Prenatal Diagnosis

Volumn 31, Issue 2, 2011, Pages 159-166

  De Mooij, Yolanda M ^a,b   Van Den Akker, Nynke M S ^a,c   Bekker, Mireille N ^b   Bartelings, Margot M ^a   Van Vugt, John M G ^b   Gittenberger De Groot, Adriana C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Lymphatic development; Noonan syndrome; Nuchal edema; Nuchal translucency

Indexed keywords

BIOLOGICAL MARKER; LYMPHOCYTE SURFACE MARKER; NEUROPILIN 1; PLATELET DERIVED GROWTH FACTOR B; PODOPLANIN; PROTEIN LYVE 1; PROTEIN PROX 1; SMOOTH MUSCLE ACTIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR CDX1; TRANSCRIPTION FACTOR FOXC2; UNCLASSIFIED DRUG; VASCULOTROPIN A; VON WILLEBRAND FACTOR;

ARTICLE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOLYMPHATIC SAC; ENDOTHELIUM; ERYTHROCYTE; FETUS; FETUS KARYOTYPING; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; NOONAN SYNDROME; NUCHAL TRANSLUCENCY MEASUREMENT; PRIORITY JOURNAL;

ENDOTHELIUM, LYMPHATIC; FEMALE; FETAL DEVELOPMENT; HUMANS; KARYOTYPING; LYMPHATIC DISEASES; LYMPHATIC SYSTEM; NOONAN SYNDROME; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; ULTRASONOGRAPHY, PRENATAL;

ERINACEIDAE;

EID: 79251498665     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2666     Document Type: Article

References (29)

1. Achiron R, Heggesh J, Grisaru D, et al. 2000. Noonan syndrome: a cryptic condition in early gestation. Am J Med Genet 92(3): 159-165.
2. Araki T, Chan G, Newbigging S, Morikawa L, Bronson RT, Neel BG. 2009. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. Proc Natl Acad Sci USA 106(12): 4736-4741.
3. Bekker MN, van den Akker NSM, Bartelings MM, et al. 2006. Nuchal edema and venous-lymphatic phenotype disturbance in human fetuses and mouse embryos with aneuploidy. J Soc Gynecol Investig 13: 209-216.
4. Bekker MN, Van Den Akker NM, de Mooij YM, Bartelings MM, Van Vugt JM, Gittenberger-de Groot AC. 2008. Jugular lymphatic maldevelopment in Turner syndrome and trisomy 21: different anomalies leading to nuchal edema. Reprod Sci 15(3): 295-304.
5. Bellini C, Rutigliani M, Boccardo FM, et al. 2009. Nuchal translucency and lymphatic system maldevelopment. J Perinat Med 37(6): 673-676.
6. Bilardo CM, Pajkrt E, de GI, Mol BW, Bleker OP. 1998. Outcome of fetuses with enlarged nuchal translucency and normal karyotype. Ultrasound Obstet Gynecol 11(6): 401-406.
7. Bilardo CM, Muller MA, Pajkrt E, Clur SA, van Zalen MM, Bijlsma EK. 2007. Increased nuchal translucency thickness and normal karyotype: time for parental reassurance. Ultrasound Obstet Gynecol 30(1): 11-18.
8. de Mooij YM, Van Den Akker NM, Bekker MN, et al. 2009. Abnormal Shh and FOXC2 expression correlates with aberrant lymphatic development in human fetuses with increased nuchal translucency. Prenat Diagn 29(9): 840-846.
9. Flamme I, von RM, Drexler HC, Syed-Ali S, Risau W. 1995. Overexpression of vascular endothelial growth factor in the avian embryo induces hypervascularization and increased vascular permeability without alterations of embryonic pattern formation. Dev Biol 171(2): 399-414.
10. Gittenberger-de Groot AC, Van Den Akker NM, Bartelings MM, Webb S, Van Vugt JM, Haak MC. 2004. Abnormal lymphatic development in trisomy 16 mouse embryos precedes nuchal edema. Dev Dyn 230(2): 378-384.
11. Haak MC, Bartelings MM, Jackson DG, Webb S, Van Vugt JM, Gittenberger-de Groot AC. 2002. Increased nuchal translucency is associated with jugular lymphatic distension. Hum Reprod 17(4): 1086-1092.
12. Hyett JA, Perdu M, Sharland GK, Snijders RS, Nicolaides KH. 1997. Increased nuchal translucency at 10-14 weeks of gestation as a marker for major cardiac defects. Ultrasound Obstet Gynecol 10(4): 242-246.
13. Kano MR, Morishita Y, Iwata C, et al. 2005. VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFRbeta signaling. J Cell Sci 118(Pt 16): 3759-3768.
14. Ko JM, Kim JM, Kim GH, Yoo HW. 2008. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome. J Hum Genet 53(11-12): 999-1006.
15. Larcher F, Murillas R, Bolontrade M, Conti CJ, Jorcano JL. 1998. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 17(3): 303-311.
16. Lawson ND, Vogel AM, Weinstein BM. 2002. sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev Cell 3(1): 127-136.
17. Lymboussaki A, Olofsson B, Eriksson U, Alitalo K. 1999. Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping binding sites in embryonic endothelia and distinct sites in differentiated adult endothelia. Circ Res 85(11): 992-999.
18. Pandya PP, Santiago C, Snijders RJ, Nicolaides KH. 1995. First trimester fetal nuchal translucency. Curr Opin Obstet Gynecol 7(2): 95-102.
19. Petrova TV, Makinen T, Makela TP, et al. 2002. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J 21(17): 4593-4599.
20. Pola R, Ling LE, Silver M, et al. 2001. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med 7(6): 706-711.
21. Reynders CS, Pauker SP, Benacerraf BR. 1997. First trimester isolated fetal nuchal lucency: significance and outcome. J ltrasound Med 16(2): 101-105.
22. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. 1998. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 352(9125): 343-346.
23. Souka AP, Snijders RJ, Novakov A, Soares W, Nicolaides KH. 1998. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 11(6): 391-400.
24. Souka AP, Krampl E, Bakalis S, Heath V, Nicolaides KH. 2001. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet Gynecol 18(1): 9-17.
25. Souka AP, Von Kaisenberg CS, Hyett JA, Sonek JD, Nicolaides KH. 2005. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 192(4): 1005-1021.
26. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. 1999. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 13(4): 231-237.
27. Stalmans I, Lambrechts D, De Smet F, et al. 2003. VEGF: a modifier of the del22q11 (DiGeorge) syndrome?. Nat Med 9(2): 173-182.
28. Webb S, Brown NA, Anderson RH. 1997. Cardiac morphology at late fetal stages in the mouse with trisomy 16: consequences for different formation of the atrioventricular junction when compared to humans with trisomy 21. Cardiovasc Res 34(3): 515-524.
29. Wigle JT, Oliver G. 1999. Prox1 function is required for the development of the murine lymphatic system. Cell 98(6): 769-778.